Myometrial dysplasia (atypical myometrial hyperplasia).
Although precursor lesions are well known for cervical and endometrial neoplasms, precursor lesions are not currently recognized for the most common tumor of the uterus-leiomyomas. Myometrial hyperplasia has been recently described and evaluated by morphometry, but its relationship to uterine leiomyomas has not been systematically explored. Myometrial dysplasia (atypical myometrial hyperplasia) has not been previously recognized. We herein report a case of myometrial dysplasia with immunostains for proliferation marker MIB-1 (Ki-67) and for p53. The paradoxical rarity of myometrial dysplasia is considered in comparison to the striking frequency of uterine leiomyomas.
Cramer
Stewart F
SF
Department of Pathology, Rochester General Hospital, University of Rochester School of Medicine, Rochester, NY 14621, USA. stewart.cramer@viahealth.org
Newcomb
Patricia M
PM
Bonfiglio
Thomas A
TA
D000328:Adult; D005260:Female; D006801:Humans; D006965:Hyperplasia / Q000150:complications / Q000473:pathology; D007889:Leiomyoma / Q000209:etiology / Q000473:pathology; D009215:Myometrium / Q000473:pathology*; D016159:Tumor Suppressor Protein p53 / Q000032:analysis
D016159:Tumor Suppressor Protein p53